乙苯哌嗪酮 | 7008-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 乙苯哌嗪酮
• 中文别名: 苯乙哌嗪酮；伊苯亚胺；苯乙哌酮
• 英文名称: 3.5-Dioxo-2-aethyl-2-phenyl-piperazin
• 英文别名: 3-ethyl-3-phenyl-piperazine-2,6-dione；3-Aethyl-3-phenyl-piperazin-2,6-dion；iminophenimide；3-ethyl-3-phenylpiperazine-2,6-dione
• CAS: 7008-18-6
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: ANPJDCDLXKNSPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲醇 、 sodium methylate 作用下， 生成 乙苯哌嗪酮
  参考文献：
  名称：

  3-ethyl-3-phenyl-2, 6-piperazinedione and derivatives thereof

  摘要：

  公开号：

  US02762805A1

文献信息

• Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129284A2

  公开（公告）日：1984-12-27

  Improved topical pharmaceutical compositions containing a pharmaceutically-active agent and the penetration enhancing agent 1-dodecylazacycloheptan-2-one are disclosed. This agent is used at selected levels in combination with certain C3-C4 diols or a 1-substituted azacycloalkyl-2-one. This composition provides marked transepidermal and percutaneous delivery of the selected pharmaceutically-active agent. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了含有一种药物活性剂和渗透增强剂 1-十二烷基氮杂环庚烷-2-酮的改良外用药物组合物。这种药剂与某些 C3-C4 二醇或 1-取代偶氮环烷基-2-酮结合使用时，可达到选定的水平。这种组合物能明显地经皮和经皮给药。此外，还公开了一种全身或局部治疗对所选活性剂有反应的某些病理和病症的方法。
• Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129285A2

  公开（公告）日：1984-12-27

  Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration-enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and percutaneous delivery of the active selected. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了一种外用药物组合物，该组合物包含一种药物活性剂和一种新型的渗透增强载体或载体。载体或载体包括 N-（2-羟乙基）吡咯烷酮和 "细胞包膜紊乱化合物 "的二元组合。这些组合物能明显地经皮和经皮递送所选的活性物质。此外，还公开了一种全身或局部治疗对所选活性物质有反应的某些病理和病症的方法。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• EP0129285B1
  申请人：——

  公开号：EP0129285B1

  公开（公告）日：1991-05-15
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13